On the other hand, previous analyses of patients with T790M NSCLC reported that patients with clearance of detectable EGFR T790M had a shorter median time to treatment discontinuation than those with retained EGFR T790M (6.1 months vs. 15.2 months, respectively) [24,25]. Here, EGFR is linked to non-small cell lung carcinoma.